OMC
CLSD

Old Mission Capital’s Clearside Biomedical CLSD Stock Holding History

Old Mission Capital’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,091
Closed -$45K – 1380
2021
Q4 		$45K Buy
+1,091
New +$70.7K ﹤0.01% 947

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Old Mission Capital's CLSD Position: Q1 2022 in Review

Old Mission Capital sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 1,091 shares — an estimated $45K sold.

Old Mission Capital first reported a position in CLSD in Q4 2021 and held it in 1 quarter. The position peaked at $45K in Q4 2021. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • Old Mission Capital reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • Old Mission Capital sold 1,091 Clearside Biomedical shares in Q1 2022, an estimated $45K.
  • Old Mission Capital first reported a position in Clearside Biomedical in Q4 2021 and held it in 1 quarter.
  • Old Mission Capital's Clearside Biomedical position peaked at $45K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Old Mission Capital's 13F filing for Q1 2022, filed 13 May 2022.